To better understand the place and the goals of CarboHyde, a private preclinical pharma startup from the EU, a short interview was performed with József Tóth Ph.D., Founder, and CEO of CarboHyde.
Read the full interview below in pdf form
Cyclo Therapeutics, Inc. goes for Phase 2b Study of Trappsol® Cyclo™ for treating early Alzheimer’s disease.
See full post…
A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford University, The National Institutes of Health, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI), Ludwig-Maximilians-Universität München, Whitehead Institute for Biomedical Research, University of Virginia School of Medicine and David Sabatini!
Full article on nature.com
What a great day when we can celebrate Carolyn Bertozzi, a pioneer in glycochemistry, and the fathers of click reaction Barry Sharpless and Morten Meldal, whose innovation we use day-by-day in our humble research.
Thank you for your groundbreaking work that enables many and more new discoveries!
Funding of translational research, using blockchain, NFTs, and a decentralized ownership and decision-making platform? One thing is for sure, it is not a sci-fi anymore.
We are happy to report on the acceptance of Tamas Sohajda‘s new patent on the use of single isomer chemically modified cyclodextrin for treating lysosomal storage diseases. Sugammadex and similar compounds are mentioned as potential active ingredients in this patent.
Our group has always been fond of photodynamic therapy, and here is a great example of why: β-galactosidase activated PDT for selective imaging and targeted treatment of glioblastoma delivered by Orta Doğu Teknik Üniversitesi / Middle East Technical University and Koç University Gorkem Gunbas Toghrul Almammadov Safacan Kölemen
Full article: https://pubs.acs.org/doi/10.1021/acsabm.2c00484
Automated solution-phase multiplicative synthesis of complex glycans enabled by preactivation-based, multi-component, one-pot glycosylation and continuous multiplying amplification published by Peking University. Wonderful!
A little business for today:
ZyVersa Therapeutics Inc., a clinical-stage specialty biopharmaceutical company developing, among others, a cyclodextrin drug candidate (VAR 200), announced an aggregate committed financing in support of the business combination at $10.0 million.
This investment will enable Zyversa to advance clinical evaluation of the cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress into Phase 1 trials – said Steve Glover and Daniel J. O’Connor
Read more on the ZyVersa website
Bathing in carbs: Lai-Xi Wang and his group from the University of Maryland reported the synthesis of cyclodextrin-based multivalent glycan ligands for human galectin-3. The GalNAc (Tn antigen) containing heptavalent ligand showed the highest affinity for human Gal-3 among the synthetic ligands tested, with an EC50 of 1.4 μM in binding to human Gal-3.
